BACKGROUND: Abnormal QT intervals, long QT or short QT, have been epidemiologically linked with sudden cardiac death because of ventricular fibrillation (VF). Consequently, Food and Drug Administration recommends testing all pharmacological agents for QT toxicity as a risk factor for cardiac toxicity. Such tests assess QT/QTc interval, which represents ventricular depolarization and repolarization. However, the current QT toxicity analysis does not account for the well-known anisotropy in cardiac tissue conductivity. Mines demonstrated in 1913 that cardiac wavelength (λ) determines inducibility of reentrant arrhythmia, where both repolarization time or action potential duration and conduction velocity determine λ=action potential duration×conduction velocity. We aimed to determine the role of anisotropic wavelength in inducibility of VF in explanted human left ventricular preparations. We tested the hypothesis that 3-dimensional cardiac wavelength, which takes into account anisotropic cardiac tissue conductivity, can accurately predict VF sustainability.
V entricular tachyarrhythmias, including ventricular tachycardia (VT) and ventricular fibrillation (VF), account for >700 000 sudden cardiac deaths in the United States and Europe annually. 1 Despite decades of scientific inquiry, our understanding of VT/ VF mechanisms remains a work in progress, hampered by the lack of 3-dimensional (3D) electrophysiological mapping with sufficient resolution, the complexity of ventricular anatomy, differences in pathophysiological mechanisms, anatomic and genetic determinants, and pathogeneses of various VT/VF. Ventricular arrhythmia can be initiated from abnormal impulse formation (eg, early or delayed afterdepolarizations) or abnormal impulse conduction (eg, block and reentry). 2 However, reentry is believed to be the primary mechanism for VT/ VF maintenance.
Reentry refers to the persisting activation sequence of a wavefront that repeatedly propagates around an anatomic or functional core. In 1913, Mines 3 framed the concept of reentry, as circus movement theory, and determined the conditions necessary for reentry to occur: unidirectional block, region of slow conduction, and recirculation of excitation wavefront to its site of origin. Garrey 4 showed that a critical mass of tissue was required to sustain arrhythmia. Lewis 5 demonstrated the mechanism of reentry in cases of atrial fibrillation and proposed the single mother reentry hypothesis, which was later extrapolated by Gurvich 6 to demonstrate VF. Allessie et al 7 and Jalife 8 provided convincing experimental evidence in support of reentrant hypothesis of tachyarrhythmias, now referred to as mother rotor hypothesis. Moe 9 proposed an alternative reentrant mechanism of fibrillation known as the multiple wavelet theory and demonstrated using a 2-dimensional (2D) computer model that arrhythmia is the result of randomly propagating wave fronts, ever changing in number and direction. This was later validated experimentally in atrial fibrillation and VF. 10 To date, it remains controversial whether mother rotor or multiple wavelets are responsible for VF. Furthermore, Tabereaux et al 11 presented evidence suggesting that VF of long duration could be because of focal activity of Purkinje fibers in contrast to VF of short duration, which is reentrant.
Mines demonstrated that the path length of reentry needs to be equal to or greater than the wavelength of the circulating excitation wave to sustain reentrant arrhythmia. Cardiac wavelength (λ) is a mathematical construct defined as the product of conduction velocity (CV) and refractory period (or action potential duration [APD] ) and measures the distance traveled by an excitation wave during the refractory period. Therefore, conditions that either shorten refractory period or slow conduction will result in shorter wavelength and thus facilitate the initiation and maintenance of reentrant arrhythmia. However, APD and CV are rate dependent and disease dependent, and consequently, wavelength is not constant but a dynamically varying function of space and time. Moreover, path length of functional reentry is modulated by critical curvature of propagating wavefront. 12 The critical mass required to sustain arrhythmia is often estimated as a 2D surface area, whereas the corresponding wavelength is calculated as 1-dimensional metric. However, reentrant ventricular arrhythmia is a 3D phenomenon propagating in the 3D ventricular tissue. Therefore, we extended the idea of Garrey and Mines to 3D with the implication that 3D reentrant arrhythmia can be initiated and sustained when the critical cardiac tissue volume (V T ) is greater than wavelength volume (V λ ). Moreover, because of anisotropic nature of CV, wavelength should be calculated for all 3 dimensions independently: longitudinal (λ L ), transverse (λ TV ), and transmural (λ TM ). We think such an approach would allow for more accurate predictive relationship between wavelength and ability to sustain reentrant arrhythmias.
Changes in QT interval, caused by genetic mutations, drugs, or environmental factors, are associated with sudden cardiac death. Thus, Food and Drug Administration requires QT toxicity tests in all pharmacological agents under development. However, this test is ambiguous because both long and short QT intervals have been epidemiologically linked with sudden cardiac deaths because of VF. We, therefore, aimed to determine the role of wavelength in sustainability of VF in explanted human left ventricular (LV) preparations. We hypothesized that QT interval alone is not sufficient to determine VF inducibility, because it underestimates the second important component of wavelength: anisotropic and rate-dependent CV.
To test this hypothesis, we conducted 4-sided optical mapping of coronary perfused human LV wedge
WHAT IS KNOWN?
• Pharmacological agents, including noncardiac drugs, under development are tested for cardiac toxicity by evaluating QT interval (QT toxicity test).
• Mechanisms of QT toxicity (abnormal QT intervals) are controversial because both long and short QT were reported as proarrhythmic.
WHAT THE STUDY ADDS?
• Cardiac 3-dimensional wavelength volume, defined as the product of cardiac wavelengths in longitudinal, transverse, and transmural directions, can determine sustainability of arrhythmia.
• Ventricular arrhythmia is sustained only when the cardiac tissue volume is greater than critical cardiac wavelength volume.
preparation subjected to pharmacological treatment by pinacidil and glybenclamide to modulate repolarization. This included measurements of epicardial longitudinal, epicardial transverse, and transmural CV, epicardial and transmural APD, from which λ L , λ TV , and λ TM were calculated. We specifically tested the hypothesis that ratio between V T and the wavelength 3D volume can predict sustainability of VT/VF. Our data demonstrate for the first time that V λ is a predictive biomarker for arrhythmia susceptibility in the human LV.
MATERIALS AND METHODS
The data, analytic methods, and study materials will be made available to other researchers for the purposes of reproducing the results or replicating the procedure. This material will be available at the George Washington University in the District of Columbia.
Donor Heart Procurement
All studies using human heart tissue were approved by the Institutional Review Board (Office of Human Research) at the George Washington University. In total, for this study, we procured 30 deidentified donor human hearts from Washington Regional Transplant Community in Washington, DC. All hearts were arrested using ice-cold cardioplegic solution in the operating room and transported to the laboratory for dissection and electrophysiological experiments. A complete list of hearts used in the study with body mass index, cause of death, left ventricular ejection fraction (listed when available), and documented arrhythmia risk factors is shown in the Figure 1 .
Study Design
This was a prospective, nonrandomized study to test the hypothesis that reentrant ventricular arrhythmia can be initiated and sustained when the critical cardiac V T is greater than V λ . Data were not blinded. The first 12 donor hearts (group 1) were used to conduct exploratory research, including development of study protocol, techniques for LV wedge dissection and preparation, and acquiring data for pinacidil dose-response curve. We did not include results from this group in our data analysis; however, data from this group have been included in Figures I through III in the Data Supplement. Incidentally, we found that the fluorescent voltage sensitive dye (Di-4-ANEPPS) used for the optical mapping experiments in the first group was not optimal for acquiring data from the epicardium because it typically has a layer of fat covering it. Ergo, for the remaining 18 donor hearts (group 2), we used Di-4-ANBDQBS as the fluorescent voltage sensitive dye, which enables data acquisition from a tissue depth of ≤4 mm (compared with 2.5 mm using the Di-4-ANEPPS). 13 We used 4 donor hearts from group 2 for development of the panoramic optical mapping experimental setup. The remaining 14 donor hearts from group 2 were subjected to the arrhythmia study protocol described below. All data from 30 donor hearts are available as part of the Data Supplement.
Experimental Preparation
Human LV wedge preparations were used for experiments, as described previously. Briefly, wedges from the posterolateral LV free wall (Figure 2A ) perfused via the left marginal artery were dissected, cannulated, and mounted in a tissue chamber with 4 surfaces (epicardium, endocardium, and the 2 transmural sides) facing 4 CMOS cameras of the optical apparatus ( Figure 2B ). Preparations were perfused with oxygenated Tyrode solution maintained at 37°C, with a perfusion pressure of 60 to 80 mm Hg. The preparation was washed with 2 L of Tyrode solution to remove excess transplant solution and restore basal electrophysiology. Tissue was immobilized by blebbistatin (10-15 μM) to suppress motion artifacts in optical recordings, without adverse electrophysiological effects.
14 Di-4-ANBDQBS was used to map transmembrane potential as described previously. 15 Pseudo-ECGs were recorded with Ag/AgCl electrodes placed on either side of the LV wedge. Two platinum-iridium tipped bipolar pacing electrodes were placed, one on the epicardial surface and the other on the transmural surface within the field of view to accurately assess longitudinal, transverse, and transmural conduction. Optical action potentials were mapped from ≈5×5 cm field of view from the 4 surfaces using 4 MiCAM05 (SciMedia, CA) CMOS cameras with high spatial and temporal resolutions (100×100 pixels; sampling frequency, 1 KHz).
Study Protocol
Tissue was paced from the epicardium or the transmural surface using a dynamic restitution protocol (S1S1) to assess the rate dependence of APD and CV, from which cardiac wavelength (λ) was calculated. Pacing current was adjusted to twice the diastolic pacing threshold starting at pacing cycle length (CL) of 2000 ms and progressively decreasing to functional refractory period. The tissue was then treated with escalating concentrations of pinacidil (5, 15, 25, 50 , and 100 μM), and the restitution protocol was repeated, until arrhythmia was induced. Thus, ventricular arrhythmias were pace-induced using the S1S1 protocol. All arrhythmias thus induced were sustained and lasted for at least 15 minutes before they were chemically terminated. Specifically, the tissue was treated with glybenclamide (50 or 100 μM) after pinacidil washout resulting in arrhythmia termination, which allowed to repeat the restitution protocol ( Figure 2C ). During the pinacidil washout, in 3 wedge preparations, arrhythmia self-terminated, and consequently, it was not treated with glybenclamide. It has been shown from a previous study that the tissue retains its electrophysiological properties for 3 hours while in an experimental bath. 16 Accordingly, we constrained each experiment to a maximum of 5 iterations of restitution protocol (eg, baseline, pinacidil at ≤3 different concentrations, and glybenclamide).
Data Processing
All optical signals were processed with open-source MATLAB software: Rhythm. 17 Briefly, each pixel was spatially filtered with a 3×3 uniform average bin, the temporal sequences were low-pass filtered using a Finite Impulse Response filter with a cutoff frequency of 100 Hz, drift in the baseline was removed with a polynomial fit subtraction, and the magnitude of the fluorescent change was normalized ( Figure I in the Data Supplement). Activation times were determined by dV/dt max and used to calculate CV in longitudinal, transverse, and transmural directions ( Figure 2D ). Whenever CV could not reliably be calculated because of heavy epicardial fat accumulation, CV data was imputed with single imputation by using mean substitution. APDs were calculated at 80% repolarization. Wavelength (λ) was calculated as a product of APD at 80% repolarization (APD80) and CV for all 3 directions: λ L , λ TV , and λ TM . V λ was defined as the product of all 3 wavelengths. Wedge V T was calculated using the Archimedes water displacement method. A pseudo-QT (pQT) interval was defined as the time interval between the earliest tissue activation and the latest tissue repolarization and was used for comparison. Arrhythmia processing entailed calculating dominant frequency (DF), regularity index (RI), in addition to wavefront and phase dynamics. DF was evaluated for each pixel as the frequency band with maximal power on a periodogram calculated with a fast Fourier transform at resolution of 0.25 Hz. RI was defined as the ratio of power within a 1.5 Hz band centered on the DF and the total power spectrum from 0 to 100 Hz. A perfect sine wave with a single frequency yields an RI of 1. Before converting the optical signals into phase domain, additional levels of preconditioning were applied to arrhythmia data. The signals were filtered with a low-pass finite impulse response filter with a cutoff frequency of 50 Hz. The processed signals were transformed into the phase domain ( Figure 2E ) using the Hilbert transform. 18 Wavefronts were defined as the isophase lines along φ=π/2. The number of discrete wavefronts was calculated for each field of view (epicardium, endocardium, and 2 transmural surfaces) with a sampling frequency of 50 Hz. Phase singularities (PS) were calculated as nonzero topological charges constrained to the isophase wavefronts (within 5-pixel radius) in each time frame. PS were considered distinct if they were >5 pixels apart in a single frame. Moreover, PS with life span of <10 ms were treated as false-positives and not included in the analysis. Stable PS were arbitrarily defined as lasting at least 1 CL. PS meandering (distance traveled) and displacement were calculated by tracking the individual PS trajectories across their life spans.
Statistical Analysis
All means characterizing the spatial average of a single study are represented as sample mean±SD. All means that characterize average trends across the cohort of donor hearts are reported as sample mean±SEM. Ordinary 2-way ANOVA with multiple comparisons and post hoc Holm-Sidak or Tukey honest significant difference multiple-comparison test was used for APD, CV, and wavelength comparisons. Data points for all pacing CLs across the cohort of hearts were pooled into 2 groups: arrhythmia not inducible (V T <V λ ) and arrhythmia is inducible (V T ≥V λ ). A statistical comparison between the 2 groups was done using the Fisher exact test. Grubb test was used to identify and remove any outliers. Significance was defined as P <0.05.
RESULTS

Anisotropic CV
CV was measured at different pacing rates along the longitudinal, transverse, and transmural axes from 14 donor hearts (group 2). At pacing rate of 60 beats per minute (bpm), under control conditions, the average longitudinal CV, CV L was 77.1±1.0 cm/s (n=8), whereas the average transverse and transmural conduction velocities were CV TV =27.9±0.6 cm/s (n=14) and CV TM =34.1±1.2 cm/s (n=13; Figure 3A ). Pinacidil treatment (25 μM) did not significantly change longitudinal (74.2±0.7 cm/s; n=6), transverse (26.6±0.5 cm/s; n=9), and transmural (32.6±1.0 cm/s; n=10) conduction velocities (P=0.17, P=0.56, and P=0.45, respectively; ordinary 2-way ANOVA with multiple comparisons and post hoc Tukey honest significant difference). Subsequent administration of glybenclamide (50 μM) resulted in small but statistically significant difference (P=0.03) in CV L =72.4±1.1 cm/s (n=4) but not in CV TV =25.9±1.2 cm/s (n=6) and CV TM =32.9±1.2 cm/s (n=5), P=0.35 and P=0.89, respectively. The CV dynamic restitution curves ( Figure 3B ; Figure IV in the Data Supplement) measured by the S1S1 protocol noted expected statistically significant decrease in conduction (P<0.0001) with increasing heart rate. At pacing rate of 240 bpm, under control conditions, the average CVs were CV L =53.9±1.1 cm/s (n=5), CV TV =22.7±0.5 cm/s (n=6), and CV TM =31.1±0.7 cm/s (n=3), respectively. At pacing rate of 480 bpm, after pinacidil treatment (25 μM), the average CVs were CV L =46.5±0.9 cm/s (n=5), CV TV =20.1±1.3 cm/s (n=5), and CV TM =26.3±3.3 cm/s (n=5), respectively. We also measured CV under control conditions with sex as the biological variable. However, we did not find any statistically significant CV differences (n=7, N=14) between male and female donor hearts ( Figure 3C ).
APD at 80% of Repolarization
APD80 was measured along the epicardial, endocardial, and transmural surfaces from 18 donor hearts (group 2). At pacing rate of 60 bpm, under baseline conditions, average epicardial APD80 was 397±15 ms (n=18), average endocardial APD80 was 414±67 ms (n=18), and average transmural APD80 was 402±14 ms (n=18; Figure 4A ). There were no statistically significant differences noted in APD80 measurements across the 3 surfaces (epicardial versus endocardium, P=0.66; epicardial versus transmural, P=0.96; and endocardial versus transmural, P=0.81, respectively; ordinary 2-way ANOVA with multiple comparisons and post hoc Tukey honest significant difference). Pinacidil treatment (25 μM) significantly reduced (P<0.0001) the APD80 values across the 3 surfaces: epicardium (136±16 ms; n=12), endocardium (164±21 ms; n=12), and transmural (141±16 ms; n=12). Administration of glybenclamide (50 μM) mitigated the effects of pinacidil and almost restored APD80 to baseline at 60 bpm with average epicardial APD80 at 355±14 ms (n=7), average endocardial APD80 at 372±19 ms (n=7), and average transmural APD80 at 363±18 ms (n=7), respectively. The APD80 dynamic restitution curves ( Figure 4B ; Figure V in the Data Supplement) showed increasingly homogeneous dispersion of repolarization across the 3 surfaces with increasing heart rates. Pinacidil administration dramatically shifted the APD80 restitution curves downward. Indeed, at the pacing rate of 480 bpm, the average APD80 values were as follows: epicardium (63±4 ms; n=9), endocardium (65±4 ms; n=9), and transmural (65±4 ms; n=9), respectively. Glybenclamide (50 μM) administration shifted the APD80 rate dependence curves upward nearly to the baseline conditions. APD80 measured across male and female donor hearts showed slightly longer APD in women especially at lower heart rates ( Figure 4C ). However, they were not statistically significant (30 bpm, P=0.37; 60 bpm, P=0.35; 120 bpm, P=0.99; and 240 bpm, P=0.98; ordinary 2-way ANOVA with multiple comparisons and post hoc Tukey honest significant difference, n=9, N=18).
Cardiac Wavelength (λ)
Wavelength was calculated along the 3 axes: λ L , λ TV , and λ TM from 14 donor hearts (group 2). V λ was calculated as the product of the 3 wavelengths: V λ =λ L ×λ TV ×λ TM . The wavelength restitution curves ( Figure 5A ; Figure VI in the Data Supplement) followed a similar trend as the APD80 restitution curves but had a higher slope as compared with either APD or CV restitution curves. Under baseline conditions, at pacing rate of 240 bpm, the wavelength averages were: λ L =9.6±0.6 cm, λ TV =4.2±0.3 cm, and λ TM =5.8±0.2 cm, respectively (n=7). The corresponding average V λ =246±42.1 cm 3 . Pinacidil (25 μM) administration dramatically reduced the wavelengths and volume. At pacing rate of 480 bpm, the corresponding values were as follows: λ L =3.0±0.2 cm, λ TV =1.3±0.1 cm, λ TM =1.7± 0.2 cm, and V λ =7.4± 1.5 cm 3 (n=9). We hypothesized that for arrhythmia to sustain, V T had to be larger than the V λ multiplied by an arrhythmia vulnerability coefficient κ ( Figure 5B ). Thus, we empirically determined κ as the ratio of V T to V λ (V T /V λ ), at which sustained VT/VF was inducible. We found that the average V T /V λ at which arrhythmia could be reliably induced and sustained was above κ=4.4±0.6 (n=11). Under control conditions, arrhythmia could not be induced as V T /V λ was well below κ and ergo in the safe zone. However, there was one instance (donor heart No. 18) where arrhythmia was induced under control conditions at pacing rate of 267 bpm. In this particular instance, V T (80 cm 3 ) was twice as large as the average size of the other LV wedge preparations V T (40 cm 3 ). The κ was calculated at 1.03. Moreover, for this heart, the corresponding values at the pacing rate of 267 bpm were as follows: λ L =6.7 cm, λ TV =2.7 cm, and λ TM =4.3 cm, respectively. Pinacidil administration increased V T /V λ , and with progressively increasing concentrations, reached κ with increasing heart rate, thus entering the vulnerable zone inducing sustained ventricular arrhythmias ( Figure 5C ). Sustained arrhythmia was induced in 10 other donor hearts-4 at pinacidil 25 μM, 2 at pinacidil 50 μM, and 4 more at pinacidil 100 μM concentrations. Treatment with glybenclamide (50 μM) decreased V T /V λ well below κ returned LV preparations back into the safe zone. Incidentally, there were 3 hearts (No. 17, 19, and 27) where we were not able to induce arrhythmia using the S1S1 protocol even with pinacidil administration (25 μM) resulting in V T /V λ being at 10.65, 4.93, and 1.51, respectively, at the pacing rate of 480 bpm. Sustained arrhythmia was only inducible in vulnerable zones when V T /V λ >1 (P<0.0001; N=14; Fischer exact test).
Pseudo-QT
pQT interval, defined from optical recordings as the time interval between the earliest tissue activation and the latest tissue repolarization ( Figure 6 ) and corrected for heart rate variability using the Fridericia formula 19 (corrected pQT interval), was calculated from 14 donor hearts (group 2). Under baseline conditions, we were unable to induce arrhythmia with QT intervals >500 ms. This was associated with cardiac V λ being greater than the V T and, therefore, in the safe zone (κ<1). In one instance (donor heart No. 18), where arrhythmia was induced under control conditions at 
. Action potential duration (N=18).
A, Representative action potential duration at 80% repolarization (APD80) measurements at 60 beats per minute from epicardial (epi), endocardial (endo), and transmural (trans) surfaces at baseline, followed by pinacidil (25 μM) and glybenclamide (50 μM) administration. There were no statistically significant differences noted in APD80 measurements across the 3 surfaces (epi vs endo, P=0.66; epi vs trans, P=0.96; and endo vs trans, P=0.81, respectively; ordinary 2-way ANOVA with multiple comparisons and post hoc Tukey honest significant difference). B, Corresponding APD80 rate dependency restitution curves showed increasingly homogeneous dispersion of repolarization across the 3 surfaces with increasing heart rates. C, APD80 measurements under control conditions across male (M) and female (F) donor hearts. Although F donor hearts had slightly longer APD80 at lower heart rates, they were not statistically significant (n=9/9; M/F).
pacing rate of 267 bpm, the corrected pQT interval was 345 ms and the corresponding cardiac V λ was less than the V T (κ=1.03). Pinacidil administration shortened QT intervals to <300 ms, and with increasing heart rate, entered the vulnerable zone inducing sustained ventricular arrhythmias. Sustained arrhythmia was induced in 10 other donor hearts-4 at pinacidil 25 μM, 2 at pinacidil 50 μM, and 4 more at pinacidil 100 μM concentrations (mean corrected pQT interval, 230±13 ms). Treatment with glybenclamide (50 μM) increased QT intervals to near baseline conditions (corrected pQT interval, >500 ms), but we were again A, Wavelength restitution curves at control, pinacidil (25 μM), and glybenclamide (50 μM) interventions. The wavelength restitution curves followed a similar trend as the action potential duration (APD) at 80% repolarization restitution curves but had a higher slope as compared with either APD or conduction velocity restitution curves. B, Cardiac wavelengths along the 3 axes and the corresponding wavelength volume under control conditions at 240 beats per minute (bpm), after pinacidil (25 μM) administration at 480 bpm and after glybenclamide (50 μM) at 120 bpm. C, Arrhythmia vulnerability curves. Sustained arrhythmia was induced (red squares) only in vulnerable zones when tissue volume (V T )/wavelength volume (V λ ) was >1 (P<0.0001; N=14; Fischer exact test). WL indicates wavelength; and WL80, wavelength at 80% repolarization.
unable to induce arrhythmia as the LV preparations returned into the safe zone (κ<1). Arrhythmia was sustained when QT interval was ≤300 ms (P<0.0001; N=14; Fisher exact test).
Reentrant Arrhythmia
Ventricular arrhythmia was induced using the S1S1 pacing protocol after pinacidil administration. The reentrant arrhythmia was primarily sustained by multiple wavelets as opposed to a single mother rotor, which was not observed. Figure 7A highlights arrhythmia dynamics from a representative data set and traces the wavefront reentry around the phase singularity through 1 CL. The corresponding DF (23.3±2.2 Hz) and RI (0.45±0.05; Figure 7B ), phase singularity meandering (0.54±0.09 cm) and total displacement (0.24±0.06 cm), and wavefront count and correlation ( Figure 7C ) are also shown. The summary arrhythmia statistics are shown in Figure VII in the Data Supplement. There were no statistically significant sex differences noted in the arrhythmia dynamics relative to DF, RI, wavefront count, or PS. Short movie clips are also included in the Data Supplement highlighting the reentrant arrhythmia (Movies I through III in the Data Supplement).
DISCUSSION
The main finding of this study was that sustained ventricular tachyarrhythmia was only inducible in the human LV tissue, if the V T was larger than V λ . Thus, we have directly demonstrated for the first time how to measure critical V T of VF, equal to V λ .
The strength of our study includes characterizing 3D wavelength dynamic restitution properties in donor human ventricular tissue for the first time and using a panoramic optical mapping system also for the first time to characterize spatiotemporal ventricular arrhythmia dynamics. Mines demonstrated that cardiac wavelength determines inducibility of reentrant arrhythmia, where both APD and CV determine λ=APD×CV. We hypothesized that repolarization alone is not sufficient to determine VF inducibility. We used pinacidil-induced arrhythmia model in combination with S1S1 pacing protocol to measure CL dependence of CV and APD. However, Mines did not know about anisotropy and pacing rate dependence of CV, which must be considered. Our data showed for the first time that CV in normal human LV has 3 distinct values: longitudinal CV L , transverse CV TV , and transmural CV TM . CV slowed with increasing heart rate. The effect of pinacidil and glybenclamide on CV was minimal in comparison. Moreover, average transmural CV, CV TM , fell along the spectrum between the longitudinal (fast) and transverse (slow) conduction. We think the intermediate range of transmural conduction could be attributed to Purkinje fibers embedded in the endocardial and subendocardial regions, as well as differences in ventricular myocyte width versus thickness. Moreover, the oblique fiber orientation along the transmural surface could also be a contributing factor.
APD measured along the epicardial, endocardial, and transmural surfaces did not show statistically significant pQT interval was calculated as the time interval between the earliest site of activation and the latest site of repolarization. The histogram is a representative recording under control conditions at 30 beats per minute. Corrected pQT interval (pQTc) was calculated using the Fridericia formula. QT restitution curves at control, pinacidil (25, 50, and 100 μM), and glybenclamide (50 μM) interventions. At shorter pQT intervals (mean pQTc, 230±13 ms), we were able to induce arrhythmia (red squares), which corresponded with the cardiac wavelength volume being less than the tissue volume (QTc threshold, ≤300 ms; P<0.0001; n=14; Fischer exact test). However, at longer QT intervals (≥500 ms), we were unable to induce arrhythmia, which was associated with cardiac wavelength volume being larger than the tissue volume. RR indicates R peak to R peak interval.
differences. Although APD shortened with increasing heart rate, there was minimal variation across the 3 surfaces especially at high heart rates, perhaps because of significant variability of repolarization across hearts. Incidentally, APD was longer in women versus men at slow heart rates. This could be attributed to decreased expression of I Kr and I Ks in women in comparison with men. Pinacidil treatment dramatically reduced APD by opening K ATP channels. Alternately, glybenclamide countered the effects of pinacidil by blocking K ATP channels and consequently allowed recovery of APD to near-baseline conditions.
Cardiac wavelength was a directional metric with slow (transverse axis), fast (longitudinal axis), and intermediate (transmural axis) components, analogous to CV. Moreover, wavelength similarly shortened with increasing heart rate given its direct relationship with APD and CV. We had hypothesized that ventricular arrhythmia could be reliably induced and sustained when V T ≥κV λ . Our data showed that the average arrhythmia vulnerability coefficient at which ventricular arrhythmia could be sustained was κ=4.4±0.6. The κ value could be explained by multiple factors. First, APD was traditionally measured at 80% repolarization to avoid signal noise contamination. It is possible that APD measured at 100% repolarization (in absence of signal noise) could converge κ closer to unity. Indeed, in one instance as noted earlier, sustained arrhythmia was induced under control conditions with κ value at 1.03. Another contributing factor could be the potential overestimation of V T , given that observed V T includes both conducting and nonconducting tissue (blood vessels, fat tissue, etc). Yet another factor could be the potential under estimation of CV, given that the available CV measurement techniques assume a 2D flat tissue surface instead of the actual curved tissue surface. Finally, functional reentry path length depends on critical curvature of propagating wavefront, which would increase the critical volume. In case of the 3 donor hearts, where we were unable to induce sustained arrhythmia, it may be that we were unable to provide the requisite premature stimulus (arrhythmia trigger) using the S1S1 protocol.
A pQT interval was calculated for comparison with the cardiac V λ index. QT interval was defined based on optical recordings as the time interval between the earliest activation and the latest repolarization and corrected for heart rate variability using the Fridericia formula. Our data showed that at QT intervals >500 ms (baseline conditions, after administration of glybenclamide), we were unable to induce arrhythmia. This could be explained by the cardiac V λ being greater than the V T . Alternately, at QT intervals <300 ms (pinacidil administration), arrhythmias were sustained. This was associated with the cardiac V λ being less than the V T . Based on these findings, we believe the QT interval is constrained in its ability to predict proarrhythmic conditions relative to cardiac V λ . One factor could be that the QT interval measurement includes conduction time (QRS duration), as opposed to CV, which is a more reliable marker for tracking arrhythmia vulnerability. Another factor could be that the QT interval is an additive measure (QRS duration+ST duration); therefore, the contribution of conduction to the overall metric can be underestimated, because usually conduction time is several folds shorter than the repolarization time. On the contrary, cardiac V λ is a multiplicative measure (CV×APD); and, therefore, both the components are equally weighted to determine arrhythmia vulnerability.
Reentrant arrhythmia was characterized by both rotors and multiple wavelets, and the 4-sided tracking of arrhythmia dynamics suggested a high level of complexity relative to arrhythmic wavefronts creation and propagation, coupled with meandering PS. Moreover, few instances of PS were stable (1%-2%). There was positive epicardium-endocardium correlation when the reentrant arrhythmia was monomorphic, relative to DF, RI, and wavefront count. However, with increasing complexity of arrhythmia (eg, polymorphic VT or VF) the epicardium-endocardium correlation exhibited increasing dissociation. There were no noticeable sex differences relative to the measured arrhythmia parameters.
Over 100 years ago, Garrey 4 started his groundbreaking paper with the observation: "Hearts of large animals fibrillate with great ease and only rarely recover from the fibrillatory state, while small hearts rarely fail to recover." Mines and Garrey postulated that the 1-dimensional wavelength compared with tissue size is a major determinant of reentry maintenance. The usefulness of 2D wavelength surface area in predicting sustainability of arrhythmia was demonstrated by Lou et al 14 and suggests the important role of wavelength in determining the arrhythmia maintenance. Indeed, for small animal hearts (eg, rabbit, rat, and mouse), and for that matter, large animal atrial tissue, wavelength can be approximated as a 2D metric with a longitudinal and transverse component, as long as transmural wavelength is greater than the thickness of the tissue. In our study, wavelength was treated as a 3D metric with an additional transmural component to account for the sizable (≈2 cm) thickness of the LV wall in comparison with transmural wavelength. Our data showed that there exists a critical V T (V T =κ V λ ) that can predict arrhythmia vulnerability.
QT interval on ECG represents the overall duration of ventricular activation and repolarization and is used to assess the potential cardiovascular toxicity of pharmaceutics. However, pharmacological agents that prolong QT interval or alternately shorten QT interval are both considered proarrhythmic. This ambiguity in the use of QT interval to assess cardiovascular toxicity suggests the need for a better marker. Based on the findings from this study, we propose that cardiovascular toxicity could be better assessed by measuring V λ in lieu of QT interval, as a more accurate and mechanistically explained biomarker of VF. Indeed, V λ could explain the apparent contradiction in arrhythmic risks because of both QT prolongation and shortening. APD shortening, and by extension, QT interval shortening, results in decrease in wavelength and, therefore, higher susceptibility to arrhythmia if CV does not change. Alternatively, APD prolongation should increase wavelength, which is actually protective against reentrant arrhythmia. Our previous study 20 on donor hearts showed that modulating the delayed rectifier currents (I Ks and I Kr ) using JNJ-303 (I Ks blocker) and E-4031 (I Kr blocker) significantly increased APD but did not induce arrhythmia. However, it is well established that during heart failure, QT prolongation is often accompanied by dramatic slowing of CV (by ≥40%), which could result in overall decrease in wavelength. 21 Indeed, the CAST trials (Cardiac Arrhythmia Suppression; CAST I and CAST II) testing the use of class Ic antiarrhythmic drugs (encainide, flecainide, and morcizine) to suppress premature ventricular complexes and consequently ventricular arrhythmia showed increased patient mortality even with successful reduction of premature ventricular complexes. 22 Class Ic drugs are known to slow conduction. For example, flecainide's action is attributed to the drug's openstate-dependent Na channel block and its Na channel association/dissociation kinetics. Moreover, the drug can also prolong ventricular repolarization. 23 Thus, QT prolongation combined with greater conduction slowing could be proarrhythmic, because the overall result is shortening of wavelength.
We acknowledge that our study has limitations. First, the cohort of donor human hearts used in this study unavoidably exhibits high variability. In addition to age differences, there is limited information available on the exact health condition. Most of the hearts we received for research were rejected for transplantation because of age restriction. Even so, we cannot discount the effect of comorbidities that may be present, such as hypertension or asymptomatic onset of heart disease. Despite these limitations, the donor human hearts represent normal human physiology as close as possible in experimental laboratory settings. Second, the measured wavelength is only an approximation of its true value, because of intrinsic error in CV measurements (treating curved tissue surface as planar) and calculating APD80. Nevertheless, the V λ so calculated is effective in predicting the sustainability of arrhythmia in this study. Third, arrhythmia vulnerability findings are constrained to pinacidil-treated and S1S1 pace-induced ventricular arrhythmia. As such, caution is recommended in extrapolation of results to nonpharmacological arrhythmia models (eg, heart failure and myocardial infarction). Additional studies are warranted to test this new VF vulnerability hypothesis under different pathophysiological and pharmacological conditions. Fourth, we cannot mitigate the effects of edema, which could develop in mechanically silent tissue preparations over time. However, to reduce this potential limitation, we restricted our experiments to 3 hours. Fifth, we did not study the impact of endocardial conduction on arrhythmia vulnerability. The trabeculated structure of endocardium made it difficult to reliably measure the endocardial CV. The endocardium may have faster conduction because of the presence of residual Purkinje fibers, which could potentially affect the findings. Tabereaux et al, 24 using canine VF model, have suggested that the Purkinje fibers may play a role in sustaining long-duration VF. It is possible that the Purkinje network could create proarrhythmic conditions, perhaps through a combination of triggered activity and reentrant wavefronts. Further studies are needed to explore the impact of Purkinje network on arrhythmia vulnerability. Sixth, although critical V λ can predict arrhythmia vulnerability and sustainability in the human LV, measuring V λ noninvasively in a clinical setting remains a challenge. 
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